Connect with us


Cure51 Raises 15 Million Euros in a Round Led by Sofinnova Partners

Cure51 secured funding in a round led by Sofinnova Partners, joined by Hitachi Ventures, Xavier Niel, and others. The company aims to investigate molecular processes enabling prolonged survival in aggressive cancers. Founded in 2022, Cure51 focuses on pancreatic adenocarcinoma, small cell lung cancer, and glioblastoma, leveraging collaborations with global cancer centers.




The French biotechnology company Cure51 has raised these funds in a round led by Sofinnova Partners, with the participation of Hitachi Ventures, Life Extension Ventures, the French telecommunications magnate Xavier Niel and Olivier Pomel, CEO and co-founder of Datadog.

Read more about Cure51 and find the most important financial news of the day with our companion app Born2Invest.

Cure51 uses computational models to understand the biological mechanisms responsible for exceptional survival cases

The objective of the Cure51 is to analyze the molecular processes that explain how there are cancer patients who survive for very long periods of time despite having very aggressive forms of the disease.

Cure51 was created in 2022 by Simon Istolainen and Nicolas Wolikow together with Paloma Cejas, a researcher at the Madrid La Paz Hospital and the Dana Farber Center in Boston, with the support of the Vall d’Hebron Institute of Oncology, the Gustave Roussy Institute, the Center León Bérard and the Charité Universitätsmedizin .

Specifically, the funding obtained will be used to treat, above all, pancreatic adenocarcinoma, small cell lung cancer and glioblastoma. To do this, Cure51 uses molecular techniques and collaborates closely with cancer centers around the world . The company is investigating how to leverage this new knowledge base for precision medicine and develop new drugs.

Sofinnova Partners currently manages 2.5 billion euros in investments

The French company works with a data collection system that it obtains through collaboration agreements with fifty medical centers with which it has built a multimodal and multiomics database of atypical patients based on their long survival.

From this database, Cure51 uses computational models to understand the biological mechanisms responsible for exceptional survival cases among patients. It does this by identifying and validating targets that can act on these interactions, which should lead to successful treatments.

Sofinnova Partners is a European venture capital firm founded in 1972 specialized in life sciences, health and sustainability with offices in Paris, London and Milan. In all its years of existence it has supported more than 500 companies. Today it manages more than 2.5 billion euros in investments.


(Featured image by Ibrahim Boran via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.